Progress in sensitive analytical approaches has opened new avenues for the detection of cells or products such as circulating cell-free DNA released by tumors. These 'liquid biopsies' are being explored in clinical trials for early cancer detection, prediction of recurrent disease, and assessment of therapeutic resistance mechanisms.
Keywords: Biomarker; Circulating tumor cells; Early detection; Liquid biopsy; Minimal residual disease; ctDNA.